Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

Core Insights - Iridex Corporation demonstrated continued revenue growth, operational efficiencies, and positive cash flow in its preliminary unaudited results for Q4 and full year 2025 [1][4] Fourth Quarter 2025 Results - Total revenue is expected to be between $14.6 million and $14.8 million, representing year-over-year growth of 15% to 17% compared to $12.7 million in the prior year quarter [8] - The company achieved positive cash flow in the fourth quarter [8] - Sold 15,800 Cyclo G6 probes, an increase from 13,300 in the prior year quarter [8] - Sold 44 Cyclo G6 Glaucoma Laser Systems, slightly down from 47 in the prior year quarter [8] Full Year 2025 Results - Total revenue is expected to be between $52.5 million and $52.7 million, reflecting year-over-year growth of 8% compared to $48.7 million in 2024 [8] - The company expects to achieve positive adjusted EBITDA for the full year 2025 [8] - Sold 57,700 Cyclo G6 probes, an increase from 55,400 in the prior year [8] - Sold 133 Cyclo G6 Glaucoma Laser Systems, up from 125 in the prior year [8] Company Overview - Iridex Corporation is a leader in developing, manufacturing, and marketing laser-based medical systems and devices for the ophthalmology market [5] - The company's proprietary MicroPulse technology offers safe and effective treatment for sight-threatening eye conditions [5]